It's looking like the end of the line for Transcept Pharmaceuticals: The troubled biotech, long in search of a buyout offer, will be forced to liquidate if it doesn't find a benefactor before the second quarter of next year, the company said.
Mylan's buyout of Agila Specialties from India's Strides Arcolab hit a hitch after the FDA issued a warning letter to one of Agila's plants. Mylan said it was holding back $250 million of the $1.75 billion payout until the regulatory issues get resolved.
The Medicines Company is taking a deep dive into hospital-borne infection treatments, signing a deal worth up to $464 million to pick up Rempex Pharmaceuticals and its fleet of pathogen-fighting drugs.
Boehringer Ingelheim is in the midst of closing down its troubled Ben Venue generic sterile injectables facility in Ohio after deciding it was not worth pouring more money into its rehabilitation. But given that there is growth in generic and contract injectable manufacturing, the German company hopes someone might want to take it off its hands.
A day removed from elating investors with a $500 million cost-cutting plan, Forest Laboratories is reportedly fielding buyout interest from pharma giant AstraZeneca, discussing a deal that could soar past $15 billion.
Volcano has approved a $200 million stock repurchase plan, a sign the company is listening to an activist investor that wants it to boost its share value and find itself a buyer.
Just weeks after selling its blood-transfusion business and announcing a new strategy focusing on pharmaceutical development, Novartis is reportedly opening the books on its animal-health business to potential buyers. Bayer may be the top suiter.
HeartWare has bought out CircuLite for as much as $350 million, acquiring a cardiac assist device for less-severe patients and broadening its offerings in the heart failure world.
A few days after the feds left Seattle-based Theraclone Sciences high and dry of funds for its midstage study of an antiflu antibody, PharmAthene is now spreading the word that it is backing out of its planned merger with the biotech.
There is growth in manufacturing sterile injectable drugs and a trend toward using prefilled syringes. India's Gland Pharma does both, and investment group KKR finds that an enticing proposition. KKR India has taken a minority stake in the drugmaker, investing $200 million, buying out the entire stake held by Evolvence India Life Sciences Fund.